Liraglutide treatment promoted the expression of IL-10 and decreased the expression of IL-12 and TNF-α, as well as modulated Kupffer cells to M2-like activation via the cAMP-PKA-STAT3 signaling pathway in a mouse-isolated primary Kupffer cell (KC) model of NAFLD. The gene discussed is TNF; the disease is metabolic dysfunction-associated steatotic liver disease.